Side-by-side · Research reference
BPC-157vsSurvodutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED9/53 cited
BPhase 3HUMAN-REVIEWED25/54 cited
BPC-157
Stable Gastric Pentadecapeptide · Healing
SQ or IM · Local · Once or twice daily
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
01Mechanism of Action
Parameter
BPC-157
Survodutide
Primary target
VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2011Sikiric 2018
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Pathway
Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2011
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Downstream effect
Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Feedback intact?
No known endogenous receptor; mechanism still under investigation
—
Origin
Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018
—
Antibody development
—
—
02Dosage Protocols
Parameter
BPC-157
Survodutide
Standard dose
250–500 mcg / dayHwang 2016
Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.
Not yet disclosed (Phase 3 ongoing)
SYNCHRONIZE Phase 3 program underway.Rubino 2026
Frequency
Once or twice daily
Split dosing reported anecdotally for chronic injury.
Once weekly
Lower / starter dose
200 mcg / day
Conservative starter for new users.
—
Evidence basis
Animal-strong + Phase 2 clinicalSikiric 2018Hwang 2016
Phase 2 RCT (obesity) · Phase 3 ongoing
Duration
2–4 weeks (acute injury); 4–8 weeks (chronic)
Anecdotal; no long-term human safety data.
—
Reconstitution
Bacteriostatic water, 1–2 mL
—
Timing
Local SQ to injury site preferred (anecdotal)
Systemic SQ also used; oral bioavailability shown in animal studies.
—
Half-life
~30 min plasma (estimated)
Tissue half-life longer; mechanism may explain durable effect.
—
03Metabolic / Fat Loss Evidence
Parameter
BPC-157
Survodutide
Primary fat target
—
Total body weight, visceral adipose tissue
Weight loss mechanism
—
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
Phase 2 efficacy
—
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
Metabolic markers
—
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
Network meta-analysis
—
Favorable efficacy profile vs other glucagon receptor agonists
Comparative efficacy
—
Network meta-analysis shows competitive efficacy in GRA class
04Side Effects & Safety
Parameter
BPC-157
Survodutide
Injection site reaction
Mild irritation (anecdotal)
—
GI symptoms
None reported in PL-14736 Phase 2
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Cardiovascular
Not reported
—
Antibody formation
No data (no long-term human trials)
—
Pregnancy / OB
Avoid — insufficient safety data
—
Long-term safety
Unknown beyond Phase 2 trial duration
—
Drug interactions
None established
—
Safety profile
—
Network meta-analysis: comparable safety to other GRAs
Serious adverse events
—
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
Injection site reactions
—
Expected with subcutaneous administration
Glucagon-related effects
—
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
Absolute Contraindications
BPC-157
- ·Pregnancy / breastfeeding
- ·Known active malignancy (theoretical VEGF concern)
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Relative Contraindications
BPC-157
- ·History of cancer
- ·Concurrent VEGF inhibitor therapy (theoretical)
- ·Acute thrombotic events
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
05Administration Protocol
Parameter
BPC-157
Survodutide
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
2. Injection site
Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
3. Timing
No strict timing requirement. Most users dose once or twice daily, often morning + evening.
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
5. Needle
27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.
06Stack Synergy
BPC-157
+ TB-500
StrongBPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.
- BPC-157
- 250–500 mcg SQ · daily
- TB-500
- 2 mg SQ · 2× per week
- Primary benefit
- Tendon/ligament/muscle repair via complementary angiogenesis + migration
Survodutide
— no documented stacks